We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03691441
Recruitment Status : Active, not recruiting
First Posted : October 1, 2018
Last Update Posted : December 11, 2020
Sponsor:
Collaborators:
Charite University, Berlin, Germany
University Medical Center Gießen and Marburg GmbH
University Hospital Ulm
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

Brief Summary:
Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer

Condition or disease Intervention/treatment Phase
Oropharyngeal Cancer Procedure: Resection Radiation: Radiotherapy Drug: Chemotherapy Procedure: Salvage neck dissection Phase 4

Detailed Description:
This trial investigates the effectiveness of transoral head and neck surgery (TOS) for locally advanced, but transorally resectable oropharyngeal cancer followed by risk-adapted adjuvant therapy versus primary radiochemotherapy (definitive chemoradiotherapy, CRTX). Both treatments are internationally accepted standards. The choice of the treatment strategy depends on the preference of the responsible attending physician and on the country of residence. Internationally, mostly definitive chemoradiotherapy is regarded as the standard of care for oropharyngeal cancer. In Germany, however, transoral surgical resection is also well established and commonly practiced. The key question therefore is whether one of the two therapies is more effective than the other in clinical daily routine under the given conditions of our health care system and with a realistic, non-ideal patient cohort. For this reason, a comparative effectiveness research (CER) concept will be applied in this setting. The aim of this trial is primarily to show a superiority of the surgical approach in terms of local and locoregional control and secondarily to compare functional outcome and quality of life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Prospective, two-arm, open label, multicenter, randomized, controlled comparative effectiveness study.

The trial is based on an event-driven design: the final analysis will be performed when all events have been observed or the study was terminated at one of the interim analyses.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer
Actual Study Start Date : January 5, 2018
Estimated Primary Completion Date : June 5, 2023
Estimated Study Completion Date : June 5, 2023

Arm Intervention/treatment
Experimental: Resection/adjuvant radio(-chemo)therapy
  • Transoral surgical resection within 4 weeks after randomization
  • Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization
  • 6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery
Procedure: Resection
Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
Other Name: Transoral Surgery

Radiation: Radiotherapy
6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible

Drug: Chemotherapy
The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.

Active Comparator: Adjuvant radio(-chemo)therapy/salvage neck dissection
  • 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization
  • 70-72 Gy, SIB possible
  • Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33
  • +/- Salvage neck dissection 12±2 weeks after treatment
Radiation: Radiotherapy
6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible

Drug: Chemotherapy
The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.

Procedure: Salvage neck dissection
+/- Salvage neck dissection 12±2 weeks after treatment




Primary Outcome Measures :
  1. Time to local or locoregional failure or death from any cause [ Time Frame: Defined as time from randomization up to 36 month ]
    The primary objective of this study is to evaluate the effectiveness of primary surgical versus non-surgical treatment of patients with locally advanced, but transorally resectable oropharyngeal cancer in terms of time to local or locoregional failure or death from any cause (LRF).


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Until 3 years after randomization ]
    Overall survival (OS) in both study arms, follow-up visits until the end of study

  2. Disease-free survival [ Time Frame: Until 3 years after randomization ]
    Disease-free survival (DFS) in both study arms. CT- Scans will be performed at month 3, month 6, 18, 30 and in case of suspicion of recurrence

  3. Effectiveness in terms of toxicity [ Time Frame: Until 3 years after randomization ]
    Effectiveness in terms of toxicity in both study arms. Monitoring of AE's/SAE's from randomization to 28 days after the last administration of IMP and/or 5 months after randomization in this trial

  4. Effectiveness in terms of morbidity [ Time Frame: Until 3 years after randomization ]
    Effectiveness in terms of morbidity (including swallowing function by MDADI Score) by late morbidity documentation in both study arms.

  5. Quality of life evaluated by patient [ Time Frame: Until 3 years after randomization ]
    Quality of life Questionnaires using QLQ H&N-43 in both study arms

  6. Quality of life evaluated by patient [ Time Frame: Until 3 years after randomization ]
    CareQuality of life Questionnaires using EORTC QLQ-C30 both study arms

  7. Cost-utility [ Time Frame: Until 3 years after randomization ]
    Cost-utility in both study armsusing Questionnaire Health Care Utilization and Productivity loss.

  8. Cost-effectiveness [ Time Frame: Until 3 years after randomization ]
    Cost-effectiveness in both study arms using Questionnaire Health Utilization and Productivity loss.


Other Outcome Measures:
  1. Tertiary objectives include comparisons of treatment effects between HPV- Status [ Time Frame: Up to 36 month ]
    Subgroup analysis of HPV-positive and HPV-negative oropharynx carcinoma



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven SCC of the oropharynx; T1, N2a-c, M0; T2, N1-2c, M0; T3, N0-2c, M0, with only amendable to transoral resection)
  • Primary tumor must be resectable through transoral approach
  • p16 immunohistochemitry by local pathology or FFPE tissue must be available for central HPV diagnostic
  • Written and signed informed consent
  • Briefing through surgeon and radiation oncologist
  • ECOG PS ≥2, Karnofsky PS ≥ 60 %
  • Age ≥ 18
  • Curative treatment intent
  • Adequate bone marrow function: leucocytes > 3.0 x 109/L, neutrophils > 1.5 x 109/L, platelets > 80 x 109/L, hemoglobin > 9.5 g/dL
  • Adequate liver function: Bilirubin < 2.0 g/dL, SGOT, SGPT, < 3 x ULN
  • If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing.
  • dental examination and appropriate dental therapy if needed prior to Confidential TopROC 2017_03_24 Version 1.0 Seite 15 von 124 beginning of radiotherapy
  • Nutritional evaluation prior to initiation of therapy and optional prophylactic gastrostomy (PEG) tube placement

Exclusion Criteria:

  • Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix
  • Unknown primary (CUP), nasopharynx, hypopharynx, laryngeal or salivary gland cancer
  • Metastatic disease
  • Serious co-morbidity, e.g. high-grade carotid artery stenosis, congestive heart failure NYHA grade 3 and 4, liver cirrhosis CHILD C
  • Hemoglobin level <9.5g/dl within 4 weeks before randomization
  • Pregnancy or lactation
  • Women of child-bearing potential with unclear contraception
  • Previous treatment with chemotherapy, radiotherapy, EGFR-targeting agents or surgery exceeding biopsy in head and neck
  • Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening
  • Social situations that limit compliance with study requirements or patients with an unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol abuse, interfering with study compliance, within 6 months prior to screening) or otherwise thought to be unreliable or incapable of complying with the requirements of the protocol
  • Patients institutionalized by official means or court order
  • Deficient

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03691441


Locations
Show Show 20 study locations
Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Charite University, Berlin, Germany
University Medical Center Gießen and Marburg GmbH
University Hospital Ulm
Investigators
Layout table for investigator information
Principal Investigator: Chia-Jung Busch, PD Dr. Universitätsklinikum Hamburg-Eppendorf
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier: NCT03691441    
Other Study ID Numbers: TopROC
First Posted: October 1, 2018    Key Record Dates
Last Update Posted: December 11, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Universitätsklinikum Hamburg-Eppendorf:
locally advanced
transorally resectable
Additional relevant MeSH terms:
Layout table for MeSH terms
Oropharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases